BACKGROUND: Cartilage and subchondral bone have recently been considered an osteochondral unit. The treatment of osteochondral lesions is still challenging, but better subchondral bone repair may result in higher quality repaired cartilage. HYPOTHESES: Alendronate accelerates bone formation in osteochondral defects and affects the quality of the repaired cartilage. STUDY DESIGN: Controlled laboratory study. METHODS: Osteochondral defects were made on the left trochleas of 50 rabbits, which were assigned to 1 of 3 groups: control, ALN (weekly subcutaneous injection of 0.14 mg/mL alendronate), and ALN-S (alendronate injection in the first 8 weeks only). They were evaluated at 4, 8, 24, and 52 weeks. Bone repair was evaluated with microcomputed tomography and histologic evaluation. Cartilage repair was evaluated with ultrasound and histologic analyses. RESULTS: At 4 weeks, the defects were filled, and cartilage-like repair tissue was observed in the ALN group, whereas the defects were incompletely filled in the control group. Alendronate treatment enhanced early bone formation and mineralization in the osteochondral defect for the first 8 weeks. The continuous injection of alendronate for 24 weeks resulted in delayed bone remodeling, but the rabbits in the ALN-S group showed good integrity of the subchondral bone plate, without delayed remodeling. At 52 weeks, the ALN-S group had a columnar arrangement of chondrocytes that had less fibrillation and looked superior to those in the ALN and control groups. Ultrasound analysis showed better quality of repaired cartilage of the ALN and ALN-S group than the control group. CONCLUSION: Alendronate accelerated bone formation without inhibiting its mineralization but thereafter inhibited bone remodeling in an osteochondral defect. The withdrawal of alendronate at 8 weeks avoided the delayed remodeling and showed better subchondral bone repair. At 52 weeks, better subchondral bone repair resulted in better cartilage quality. CLINICAL RELEVANCE: Alendronate administered in the early period accelerates bone formation and improves the quality of the repaired cartilage.
BACKGROUND:Cartilage and subchondral bone have recently been considered an osteochondral unit. The treatment of osteochondral lesions is still challenging, but better subchondral bone repair may result in higher quality repaired cartilage. HYPOTHESES: Alendronate accelerates bone formation in osteochondral defects and affects the quality of the repaired cartilage. STUDY DESIGN: Controlled laboratory study. METHODS:Osteochondral defects were made on the left trochleas of 50 rabbits, which were assigned to 1 of 3 groups: control, ALN (weekly subcutaneous injection of 0.14 mg/mL alendronate), and ALN-S (alendronate injection in the first 8 weeks only). They were evaluated at 4, 8, 24, and 52 weeks. Bone repair was evaluated with microcomputed tomography and histologic evaluation. Cartilage repair was evaluated with ultrasound and histologic analyses. RESULTS: At 4 weeks, the defects were filled, and cartilage-like repair tissue was observed in the ALN group, whereas the defects were incompletely filled in the control group. Alendronate treatment enhanced early bone formation and mineralization in the osteochondral defect for the first 8 weeks. The continuous injection of alendronate for 24 weeks resulted in delayed bone remodeling, but the rabbits in the ALN-S group showed good integrity of the subchondral bone plate, without delayed remodeling. At 52 weeks, the ALN-S group had a columnar arrangement of chondrocytes that had less fibrillation and looked superior to those in the ALN and control groups. Ultrasound analysis showed better quality of repaired cartilage of the ALN and ALN-S group than the control group. CONCLUSION:Alendronate accelerated bone formation without inhibiting its mineralization but thereafter inhibited bone remodeling in an osteochondral defect. The withdrawal of alendronate at 8 weeks avoided the delayed remodeling and showed better subchondral bone repair. At 52 weeks, better subchondral bone repair resulted in better cartilage quality. CLINICAL RELEVANCE: Alendronate administered in the early period accelerates bone formation and improves the quality of the repaired cartilage.
Authors: Christian G Pfeifer; Matthew B Fisher; Vishal Saxena; Minwook Kim; Elizabeth A Henning; David A Steinberg; George R Dodge; Robert L Mauck Journal: Tissue Eng Part C Methods Date: 2017-10-27 Impact factor: 3.056
Authors: C B Raub; S C Hsu; E F Chan; R Shirazi; A C Chen; E Chnari; E J Semler; R L Sah Journal: Osteoarthritis Cartilage Date: 2013-03-22 Impact factor: 6.576
Authors: Anthony R Martin; Jay M Patel; Ryan C Locke; Michael R Eby; Kamiel S Saleh; Matthew D Davidson; Mackenzie L Sennett; Hannah M Zlotnick; Andrew H Chang; James L Carey; Jason A Burdick; Robert L Mauck Journal: Acta Biomater Date: 2021-03-19 Impact factor: 8.947
Authors: Tomasz L Nosewicz; Mikel L Reilingh; C Niek van Dijk; Georg N Duda; Hanna Schell Journal: Knee Surg Sports Traumatol Arthrosc Date: 2011-12-21 Impact factor: 4.342
Authors: Zaitunnatakhin Zamli; Kate Robson Brown; John F Tarlton; Mike A Adams; Georgina E Torlot; Charlie Cartwright; William A Cook; Kristiina Vassilevskaja; Mohammed Sharif Journal: Biomed Res Int Date: 2014-06-18 Impact factor: 3.411